Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Exposure of Infants Who Are Breastfed to Antiepileptic Drugs—Reply

Exposure of Infants Who Are Breastfed to Antiepileptic Drugs—Reply Letters Study concept and design: Lopez, Pittock, Flanagan. no residual demyelination in 18 patients (72%) and residual Acquisition, analysis, or interpretation of data: All authors. demyelinating T2 hyperintensities in 7 patients (28%; 3 with Drafting of the manuscript: Lopez, Sechi, Buciuc, Flanagan. atrophy). All 6 follow-up spine MRI scans were normal. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Sechi, Buciuc, Lucchinetti. Obtained funding: Pittock. Discussion | We found that most patients with MOGAD had a fa- Administrative, technical, or material support: Lopez. vorable long-term outcome without secondary progression de- Study supervision: Lopez, Flanagan. spite frequent relapses, differing from that reported with mul- Conflict of Interest Disclosures: Dr Pittock reported receiving grants, personal tiple sclerosis (MS) and aquaporin-4–IgG neuromyelitis optica fees, and nonfinancial support from Alexion Pharmaceuticals; grants from spectrum disorders (NMOSDs). Grifols and the Autoimmune Encephalitis Alliance; grants, personal fees, nonfinancial support, and other from MedImmune; other support from Astellas; Our finding of just 7% having an EDSS score of 6 or greater and personal fees from UCB; and having Patent No. 8,889,102 (Application No. and 7% unilaterally blind or worse after a median of 14 years 12-678350)—Neuromyelitis Optica Autoantibodies as a Marker http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Exposure of Infants Who Are Breastfed to Antiepileptic Drugs—Reply

Loading next page...
 
/lp/american-medical-association/exposure-of-infants-who-are-breastfed-to-antiepileptic-drugs-reply-Pjf09qCiNI
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2020.3033
Publisher site
See Article on Publisher Site

Abstract

Letters Study concept and design: Lopez, Pittock, Flanagan. no residual demyelination in 18 patients (72%) and residual Acquisition, analysis, or interpretation of data: All authors. demyelinating T2 hyperintensities in 7 patients (28%; 3 with Drafting of the manuscript: Lopez, Sechi, Buciuc, Flanagan. atrophy). All 6 follow-up spine MRI scans were normal. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Sechi, Buciuc, Lucchinetti. Obtained funding: Pittock. Discussion | We found that most patients with MOGAD had a fa- Administrative, technical, or material support: Lopez. vorable long-term outcome without secondary progression de- Study supervision: Lopez, Flanagan. spite frequent relapses, differing from that reported with mul- Conflict of Interest Disclosures: Dr Pittock reported receiving grants, personal tiple sclerosis (MS) and aquaporin-4–IgG neuromyelitis optica fees, and nonfinancial support from Alexion Pharmaceuticals; grants from spectrum disorders (NMOSDs). Grifols and the Autoimmune Encephalitis Alliance; grants, personal fees, nonfinancial support, and other from MedImmune; other support from Astellas; Our finding of just 7% having an EDSS score of 6 or greater and personal fees from UCB; and having Patent No. 8,889,102 (Application No. and 7% unilaterally blind or worse after a median of 14 years 12-678350)—Neuromyelitis Optica Autoantibodies as a Marker

Journal

JAMA NeurologyAmerican Medical Association

Published: Dec 24, 2020

References